Atay Oguzhan sold $604K of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 5,334 indirectly-held shares of BillionToOne, Inc. (BLLN) at $113.17 ($0.60M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Nov 5, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a signal, but the pre‑arranged nature tempers its significance.

02

Market read

The filing provides fresh, material information for BLLN shareholders and may cause short‑term price movement.

03

What to watch

Potential upcoming financing needs or strategic repositioning not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: after‑hours filing today

Background

Form 4 filings disclose insider transactions and are primary sources for insider activity.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

CEO Atay Oguzhan sold $604K of BLLN shares via a 10b5‑1 plan, reducing his stake to 141,167 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell.

Evidence & confidence

A $600K sale by the chairman/CEO is material for a micro‑cap, but the amount is modest relative to market cap and the sale was pre‑arranged.

Market effects

Minimal impact on the broader biotech/AI sector; the sale is company‑specific.

No regional effect; the filing is U.S. SEC‑based.

Limited global relevance; only relevant to investors tracking BLLN.

Counterpoint

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • BillionToOne, Inc.

    Public biotech/AI company listed on NASDAQ under ticker BLLN.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc., reporting the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.